argenx SE American Depositary Shares (ARGX) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA...
argenx SE American Depositary Shares's revenue increased 88.4% year over year, from $2.25B to $4.24B.
Net income increased 55.1% over the same period, from $833.0M to $1.29B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 702% in total.
Total debt remained relatively stable at $47.0M.
The debt-to-equity ratio stands at 0.01, indicating a conservative leverage profile.
Operating cash flow grew 42.2% to $974.2M.
argenx SE American Depositary Shares maintains a strong net profit margin of 30.5%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $528.3M | $-408.3M | $-52.3M | $-359.9M | $-862.8M | $3.13B | $12.4M | $2.81B |
| FY2022 | $441.0M-16.5% | $-709.6M | $-251.8M | $-723.9M | $-420.3M | $4.54B | $20.0M | $4.10B |
| FY2023 | $1.27B+187.7% | $-295.1M | $291.3M | $-420.6M | $-82.7M | $6.20B | $39.1M | $5.50B |
| FY2024 | $2.25B+77.2% | $833.0M | $1.04B | $-17.8M | $685.2M | $8.68B | $47.2M | $7.32B |
| FY2025 | $4.24B+88.4% | $1.29B | $2.42B | $1.05B | $974.2M | $10.03B | $47.0M | $8.42B |
Balance Sheet Summary (FY2025)
argenx SE American Depositary Shares (ARGX) Financial Statements & Revenue History
argenx SE American Depositary Shares (ARGX) is a US-listed stock operating in the Healthcare sector trading at $819.14 with a market capitalization of $52. This page provides 5 historical financial statements for argenx SE American Depositary Shares, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, argenx SE American Depositary Shares reported revenue of $4.2 billion, representing 88.4% year-over-year growth. The net profit margin of 30.5% reflects strong profitability. The debt-to-equity ratio of 0.01 shows conservative leverage.
ARGX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows argenx SE American Depositary Shares's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ARGX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ARGX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently argenx SE American Depositary Shares converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ARGX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ARGX Financial Data
Investors use argenx SE American Depositary Shares's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ARGX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ARGX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ARGX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from argenx SE American Depositary Shares's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ARGX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.